Rodrigues T A, Sampaio A J B, Nunes I D P, Cartágenes M S S, Garcia J B S
Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, São Luís, MA, Brasil.
Braz J Med Biol Res. 2017 Aug 7;50(9):e6314. doi: 10.1590/1414-431X20176314.
Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects of decreasing the risk of fractures and an indication of reducing the progression of osteoarthritis (OA). This study aimed to investigate the effects of SrRan as either a prophylactic or a treatment drug, using an OA rat model to assess pain behavior. A monoiodoacetate (MIA)-induced knee joint OA model in Wistar rats was used. Thirty Wistar rats (both sexes, 60 days old) were distributed in five groups of 6 rats each: the control group, that received no intervention; a prophylactic group, that received oral administration of 25 mg·kg-1·day-1 of SrRan for 28 days before induction of OA; a group treated with 25 mg·kg-1·day-1 of SrRan for 28 days after OA induction; a group treated with 50 mg·kg-1·day-1 during 28 days after OA induction; and a group that received oral saline for 28 days after induction. The assessment of pain behavior was performed considering articular incapacitation (weight-bearing test), mechanical hyperalgesia (Randall Selitto test) and motor activity (rotarod test), on days 0, 7, 14, 21, and 28. This experiment did not yield a significant difference when comparing the group that received SrRan prophylactically with the groups treated with 25 or 50 mg·kg-1·day-1 and the group that received oral saline. Thus, SrRan did not provide analgesia in either treated rats or as a prophylactic drug with the tested doses. Higher doses should be tested further to achieve possible significant results.
雷奈酸锶（SrRan）是一种通常用于治疗骨质疏松症的药物，已证实具有降低骨折风险的作用，并显示出减缓骨关节炎（OA）进展的迹象。本研究旨在使用OA大鼠模型评估疼痛行为，以研究SrRan作为预防或治疗药物的效果。采用单碘乙酸盐（MIA）诱导的Wistar大鼠膝关节OA模型。30只Wistar大鼠（雌雄不限，60日龄）分为5组，每组6只：对照组，不接受任何干预；预防组，在诱导OA前28天口服25mg·kg-1·天-1的SrRan；OA诱导后用25mg·kg-1·天-1的SrRan治疗28天的组；OA诱导后用50mg·kg-1·天-1治疗28天的组；以及诱导后口服生理盐水28天的组。在第0、7、14、21和28天，通过关节失能（负重试验）、机械性痛觉过敏（Randall Selitto试验）和运动活动（转棒试验）对疼痛行为进行评估。将预防性接受SrRan的组与接受25或50mg·kg-1·天-1治疗的组以及接受口服生理盐水的组进行比较时，本实验未产生显著差异。因此，SrRan在受试大鼠中作为治疗药物或预防药物均未提供镇痛作用。应进一步测试更高剂量以获得可能的显著结果。
